-
-
-
-
-
-
-
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) launches today as a new publicly traded company
-
-
-
-
-
-
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Biohaven Pharmaceutical Holding Company Ltd. (NYSE - BHVN), Tiga Acquisition Corp. (NYSE - TINV), Lakeshore
-
-
-
-
-
-
-
Pfizer to pay $11.6 billion for Biohaven to tap migraine market
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Announces Strategic Collaboration with Pfizer (PFE) for Commercialization of Rimegepant Outside the US
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
-
-
-
-
-
-
-
Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

